6:02 PM
 | 
Dec 13, 2012
 |  BC Extra  |  Clinical News

Oncolytics gains on Phase III cancer data for Reolysin

Shares of Oncolytics Biotech Inc. (TSX:ONC; NASDAQ:ONCY) jumped on Thursday after the company reported data from the Phase III REO 018 trial evaluating IV Reolysin plus carboplatin and paclitaxel to treat platinum-refractory head and neck cancer. Oncolytics said in 105 evaluable patients...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >